NCT02176109

Brief Summary

In this study, the investigators study the prognostic role of oxidative stress metabolism and iron in Acute myeloid leukemia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2013

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

June 24, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 26, 2014

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

June 26, 2014

Status Verified

June 1, 2013

Enrollment Period

2 years

First QC Date

June 24, 2014

Last Update Submit

June 25, 2014

Conditions

IronAcute Myeloid LeukemiaDiagnosisOxydative Stress

Outcome Measures

Primary Outcomes (1)

  • overall survival Event-free survival Response to induction chemotherapy, overalll survival, event-free survival

    five years after the inclusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

de novo acute myeloid leukemic patient from 18 years to 99 years. promyelocytic leukemia excluded

You may qualify if:

  • de novo acute myeloid leukemic patient from 18 years to 99 years at diagnosis

You may not qualify if:

  • age under 18 years promelocytic leukemia secondary leukemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Grenoble

Grenoble, Isere, 38043, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

leukemic cells in order to rna and proteins study medullar plasma

MeSH Terms

Conditions

Leukemia, Myeloid, AcuteDisease

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

pascal mossuz, phd

CONTACT

pmossuz@chu-grenoble.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2014

First Posted

June 26, 2014

Study Start

June 1, 2013

Primary Completion

June 1, 2015

Study Completion

June 1, 2018

Last Updated

June 26, 2014

Record last verified: 2013-06

Locations

FR(1)